Answers are grounded in this paper and cite their sources.
There is a well-known knowledge gap regarding the efficacy and safety of medicines in children of all ages, and clinical trials and the need for new treatments were recently listed among the most important factors for child health. Pediatric clinical trials are faced with several challenges compared with trials in adults. These challenges include the fact that pediatric populations are small and heterogenous, and that there is generally less experience with pediatric clinical trials,, compared to trials in adults both on the sponsor side and at the hospitals. One specific challenge that has received little attention is the importance of adequate representation of costs in pediatric trial budgets. The aim with the present study was to describe some important aspects to consider when a pediatric clinical trial budget is reviewed and identify budget items that often need adjustments in pediatric clinical trials. We went through the budgets negotiations of the last ten trials sponsored by the pharmaceutical industry where agreements between our site, the Pediatric Clinical Research Center, and the sponsor, had been finalized. The therapy areas represented among these trials were pediatric oncology (2), neurology (4), gastroenterology, neuropsychiatry, cardiology, and nephrology. We reviewed the trial budgets and identified areas where discrepancies between the sponsor´s initial budget, and the final budget, negotiated and agreed between sponsor and site, may arise. The difference in total budget amount between the initial budget and the final budget was +60% (mean 59%, range 31 to 139%). The costs for preparation of the clinical trial, time spent for study activities, and costs for examinations were identified as key budget items for these differences. Our findings indicate that a substantial part of the trial-related costs would not be covered by the sponsor had the initial budget been accepted. A thorough review at the site and budget negotiation with the sponsor, and to have within the site team a person with specific competence for the budget review and negotiation, are therefore essential to ensure equitable responsibility for the study-related costs and avoid discontinuation of the trials. High-quality pediatric trials are essential to ensure that children have the benefit of treatments based on the same quality of evidence that guides treatment in adults.
No takes yet. Share an insight, caveat, or question.
Koulizakos et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: